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ABSTRACT 
 
 
Introduction: Gefitinib, an orally active epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitor, induces growth arrest in squamous cancer cell 
carcinoma of head and neck (SCCHN) cell lines mainly by blocking cells in G1 
and preventing them from entering the cell cycle. Clinical studies have 
demonstrated the activity of gefitinib monotherapy in SCCHN. Preclinical studies 
have shown that the combination of radiotherapy (RT) and drugs interfering with 
the EGF pathway may result in radiosensitization in squamous cell carcinomas 
that over express EGFR.  
Purpose: Two different doses of gefitinib, administered along with standard 
radiation therapy, were tested in locally advanced inoperable head and neck 
cancer who have neiver received radiotherapy or chemotherapy or undergone 
surgery for head and neck carcinoma, with the aim of finding the maximum 
tolerated dose and assessing the toxicity and activity of the combination. 
Patients and methods: The standard “3+3” design was used for the phase I study. 
Radiation therapy was given according to conventional dose and schedule. 
Gefitinib dose escalation was stopped if more than a third of patients of a given 
cohort had dose limiting toxicity (DLT). 
Results: DLT was observed in 3 out of 4 patients treated at the dose of 500 mg 
and included grade 3 stomatitis in 3 patients and grade 3 liver toxicities in 1 
patient. The dose level of 250 mg was recommended for the phase II study. Six 
confirmed objective responses were observed among 16 patients. Four patients 
had a complete response, which was confirmed in three cases; eight patients had 
a partial response, which was not confirmed in six patients. Stable disease and 
disease progression were observed in one and three patients, respectively. Median 
duration of response was 5.4 (range: 1–21) months. The observed stable disease 
lasted 7.4 months. The median progression free-survival was 6.7 months (95% 
CI: 4.5–12.1) and the median OS was 8.5 months. 
Conclusion: Our results do not support further trials with gefitinib and radiation 
therapy, according to our schedule, in this patient population. Integration of 
gefitinib within chemoradiotherapy regimens and combination with other 
biological therapies may represent the next challenge. 
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1.   BACKGROUND 
 
 
1.1 Head and Neck Cancer  
 
Head and neck cancer (HNC) is a common neoplasm with an increasingly high 
incidence, particularly in the elderly population. Approximately 36,500 new 
cases of head and neck cancer was be diagnosed in the United States  in 2003 and 
that 11,000 American deaths will result from head and neck malignancies. While 
head and neck cancer accounts for only 3% of all new cancer cases and 2% of all 
cancer deaths in the United States annually, it is the fifth most common 
malignancy worldwide (Jemal et al. 2003) and the third most prevalent cancer 
after breast and colorectal cancers, accounting for 6% of the individuals with a 
cancer diagnosis. Squamous cell carcinoma represents the most common 
histology and tobacco and alcohol are the primary etiologic agents in these 
cancers. Also genetic susceptibility and various infectious agents  can be 
implicated (Diaz et al. 2003) 
Data from the Surveillance, Epidemiology and End Results (SEER) 
program report also the majority of cancers are from the tongue (21%), gum and 
other mouth sites (15%), tonsil (11%), and salivary-gland (10%). (SEER-
http://seer.cancer.gov/publications/survival/surv/head_neck.pdf). Figure 1 display 
a rapidly decreasing slope in relative survival until sometime between 18 and 36 
months followed by a leveling off for any head and neck cancer sites. 
 
 
Fig.1: Cancer of the Head and Neck: Relative Survival Rate (%) by Primary 
Site, Ages 20+, 1988-2001  
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Patients with lip cancer had the best prognosis, with 5-year relative survival 
approximately 94%. On the other hand, cancers of the hypopharynx (5-year 
relative survival rate 30%) and “other cancers of the oral cavity and pharynx” (5-
year relative survival rate 30%) have the worst prognoses in terms of relative 
survival rates. 
 
Although early-stage head and neck cancers (especially laryngeal and oral cavity) 
have high cure rates, over 60% of HNC patients present with advanced disease.  
Cure rates decrease, of course, in locally advanced cases, whose probability 
of cure is inversely related to tumor size and even more so to the extent of regional 
node involvement. In most cases HNC is diagnosed as unresectable locally 
advanced disease whose five-year survival is < 10%. In fact, despite improvements 
in diagnosis and local management, long-term survival rates have not increased 
significantly over the past 40 years and are among the lowest worldwide of the 
major cancers (Reuter et al. 2007). 
Treatment for early stage disease involves usually surgery and radiation 
therapy (RT). The treatment of locoregionally advanced disease has evolved 
gradually from surgery as the mainstay of treatment to radiotherapy as the 
principal treatment (Kramer et al. 1987). More recently, additional benefit has 
been obtained with altered-fractionation-radiotherapy (i.e. accelerated 
fractionation or hyperfractionated radiotherapy) and with radiotherapy combined 
with chemotherapy (chemoradiotherapy) either in the definitive setting or 
following surgery, according to each center's expertise (Garden et al. 2004) 
(Cohen et al. 2004). 
Combined chemoradiotherapy has represented the mainstay of treatment  
over the last decades, but, disappontingly, the patient outcome has not 
substantially improved. The value of chemoradiotherapy is, however, 
counterbalanced by increased and often prohibitive toxicity, particularly among 
patients with coexisting medical conditions and decreased performance status.  
Although altered radiation fractionation and chemoradiotherapy had a 
favorable impact for advanced head and neck cancer patients, the outcome of 
patients presenting with stage III-IV HNC is still poor, with 5-year actuarial 
survival rates fluctuating between 30% and 40% in most trials (Licitra et al 
2004). Squamous-cell carcinoma of the head and neck (SCCHN) remains a 
challenging clinical problem, due to the persisting high rate of local and distant 
failure, as well as the occurrence of second primaries.  
Patients affected by SCCHN also face tremendous impacts on quality of 
life after definitive therapy. Despite marked advances in reconstructive surgery 
and rehabilitation, intensity-modulated radiotherapy (IMRT) and conservation 
approaches, patients continue to have significant functional deficits.  
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These compelling problems are responsable for the emerging importance 
of treatment of HNC.  
Recent research efforts have attempted to exploit biologic differences that 
may exist between normal and malignant cells, to develop tumor-specific 
therapies. During the past decade, intense research has initiated a new era of 
cancer treatment, that of molecular therapeutics. Promising preclinical studies 
have prompted the development of clinical trials testing EGFR inhibitors as 
single agent therapy or in combination with conventional cytotoxic therapy, with 
response rates lower than anticipated in the advanced disease setting. 
The potential advantages of EGFR-TKIs include ease of administration and 
no issues with infusion reactions.  
Monotherapy trials seem to show similar response rates and survival rates 
between EGFR antibodies and EGFR-TKIs in metastatic, chemotherapy-
refractoryHNC. It is unlikely that a clinical trial will directly compare the two 
approaches with RT. 
The Epidermal growth factor receptor (EGFR) is a prime target for new 
anticancer therapy, with a broad range of inhibitors currently under investigation 
(Baselga 2001). 
 
 
 
1.2 EGFR pathway and its role in HCN  
 
It was in 1980 that Cohen et collegues (1980) managed to purify the Epidermal 
growth factor receptor (EGFR), 15 years after the initial isolation of its ligand, 
EGF (Cohen 1965). EGFR is a transmembrane glycoprotein of 170 kDa, encoded 
by a gene located on chromosome 7p12 (Davies et al. 1980). It belongs to the 
ErbB receptor family (EGFR or Her-1, Her-2, Her-3, and Her-4). These receptors 
are composed of an extra-cellular ligand-binding domain, a hydrophobic 
transmembrane segment, and an intracellular tyrosine kinase domain.  
In normal cells, the expression of EGFR ranges from 40,000 to 100,000 
receptors per cell (Carpenter et al. 1979). In squamous cell carcinoma of head and 
neck EGFR and its ligand, TGF-α, are overexpressed in 80–90% of cases; the 
corresponding magnitudes of increase are 1.7-fold (P = 0.005) and 1.9-fold (P = 
0.006) respectively, when compared to controls (Grandis and Tweardy 1993). 
The nature of the protein overexpression is thought to result from enhanced 
transcription, with no apparent change in mRNA stability; gene amplification has 
been observed less frequently. TGF-α is participating in an autocrine-signalling 
pathway in transformed, but not in normal mucosal epithelial cells (Grandis et al 
1998). 
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Binding to EGFR by its natural ligands, mainly EGF or transforming growth 
factor alpha (TGF-α) results in a conformational change in the receptor, which 
promotes homodimerization with other EGFR molecules or heterodimerization 
with other HER family members (especially Her-2); dimerization results in 
subsequent autoactivation of the tyrosine kinase from the intracellular domain of 
the receptor. This process will activate an intracellular signalling pathway, 
leading to the inhibition of apoptosis, activation of cell proliferation and 
angiogenesis (Roskoski et al. 2004), as well as an increase in metastatic spread 
potential like detailed in Figure 2 (Harari and Huang 2000) were are shown the 
major signalling pathways downstream of c-erbB-receptors Binding of specific 
ligands (e.g. TGF-a) may generate homo- or heterodimeric complexes resulting 
in conformational changes in the intracellular EGFR kinase domain, which lead 
to autophosphorylation and activation. Consequently, signalling molecules, 
including growth factor receptor-bound protein-2 (Grb-2), are recruited to the 
plasma membrane. Activation of several signalling cascades is triggered 
predominately by the RAS-to-MAPK and the PI-3K/Akt pathways, resulting in 
enhanced tumour growth, survival, invasion and metastasis.  
 
 
 
Figure 2: Role of EGFR in signal transduction and tumor progression  
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Simplified schematic illustration of the EGFR system depicting EGFR, mitogen-
activated protein kinase signal transduction cascade to the nucleus, and 
stimulation of cell cycle machinery  
 
EGFR overexpression is an early event in SCCHN carcinogenesis; it is already 
present in "healthy" mucosa (field cancerization) from cancer patients, when 
compared to healthy controls; this overexpression will increase steadily in 
parallel to observed histological abnormalities, from hyperplasia to invasive 
carcinoma, through dysplasia and in situ carcinoma (Rubin Grandis et al. 1996) 
The epidermal growth factor (EGF) and its receptor (EGFR, ErbB-1, or 
HER-1) were not only shown to play an influential role in cellular growth and 
differentiation in healthy tissues, but also in tumorigenesis and the progression of 
malignant disease (Arteaga 2003). 
EGFR is overexpressed in approximately 90% of HNC and has been 
associated with worse prognosis, thereby providing a stroge rationale for clinical 
investigation of EGFR-targeting drugs in HNC (Santini et al. 1991). 
 
 
 
1.3 Targeting the EGFR in HNC  
 
There is strong evidence that supports targeting of the EGFR in cancer therapy: 
the EGFR is frequently overexpressed and/or abnormally activated in tumours 
including SCCHN, colorectal cancer, glioblastoma, or non-small-cell lung cancer. 
Particularly in SCCHN, multivariate analyses have shown EGFR levels to be an 
independent predictor of poor outcome (Rubin Grandis et al. 1996) (Ang et al. 
2002). Moreover, early studies with anti-EGFR monoclonal antibodies directed 
against the EGFR were shown to be of clinical benefit (Bonner et al. 2000).  
Although there are several potential strategies for targeting the EGFR, 
only monoclonal antibodies (mAbs) and the low molecular weight tyrosine kinase 
inhibitors (TKI) are in the most advanced stages of clinical development and will, 
therefore, be the focus of our attention. 
EGFR targeting can be considered as one of the most exploited 
approaches to a rational targeted therapy of cancer, and it can be basically 
achieved by two complementary therapeutic strategies . 
The first one targets the extracellular domain of the receptor with 
monoclonal antibodies; binding of the antibody to the EGFR prevents activation 
of the receptor by endogeneous ligands through competitive inhibition; it also 
results in internalization and degradation of the antibody-receptor complex, 
downregulating EGFR expression. Cetuximab or C225, has been the first EGFR-
targeting agent to be used in combination with radiotherapy in HNC. Bonner and 
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collegues (2006) demonstrated in a phase III randomized trial that concomitant 
radiation (RT) therapy plus cetuximab, improved locoregional control, disease-
free survival, and overall survival in locally advanced NHC patients.  
The second strategy targets the intracellular domain of the receptor with 
low-molecular-weight tyrosine kinase inhibitors (gefitinib or ZD 1839 or 
Iressa®; erlotinib, or OSI-774 or Tarceva®), competing with adenosine 
triphosphate (ATP) for its binding site on the intracellular domain of EGFR 
inhibiting EGFR-specific tyrosine kinases (Baselga and Arteaga. 2005). 
These two classes of anti-EGFR agents did not meet the expectations in clinical 
practice when used in monotherapy, resulting more often in a cytostatic than a 
cytotoxic effect (Raben et al. 2004). 
Combining EGFR inhibitors with conventional chemotherapy provided 
disappointing results so far (Burtness et al. 2005).  
 
 
 
1.4 The radiobiological rationale  
 
The effect of radiation on tumor-cell proliferation has been extensively studied in 
the setting of RT of the head and neck. Accelerated repopulation, a condition of 
enhanced cellular proliferation after exposure to ionising radiation, appears to be 
responsible, at least in part, for radioresistance of head and neck cancers. 
Preclinical evidence suggests that EGFR has an important role in the proliferative 
response to ionizing radiation, counteracting the toxic effects of RT. 
Most preclinical and clinical studies demonstrated a lower local control 
after radiation therapy in tumors overexpressing EGFR (Baumann and Kraus 
2004). 
Mechanisms of activation may be diverse, including increased EGFR 
expression (Schmidt-Ullrich et al. 1994) but one key mechanism involves 
probably ligand-stimulated activation. RT is able indeed to activate early the 
transduction signalling pathway of EGFR, through radiation-induced release of 
TGF-α, one of the EGFR ligands (Dent et al. 1999).  
The inhibition of radiation-induced activation of the EGFR signalling 
pathway is one of the factors explaining the observed synergy between RT and 
EGFR inhibition; an increase in radiosensitivity through this pathway was 
demonstrated in vitro (Tofilon et al. 2003). It has to be reminded that, at this 
point, no clear relationship has been demonstrated between EGFR expression (at 
least as measured by immunohistochemistry) and the level of radiation 
sensitization achieved with anti-EGFR. We are unable as well to identify tumors 
that are radioresistant by virtue of EGFR signalling, and are thus likely to become 
radiosensitized by EGFR inhibitors (Sartor 2004). 
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A former study in 140 patients with primary laryngeal squamous-cell 
carcinoma showed that the 5-year survival rate was 81% for patients with EGFR 
non-expressing tumors, compared with 25% for patients with EGFR-expressing 
tumors (P < 0.0001) (Maurizi et al. 1996) These results were also confirmed by 
others (Demiral et al. 2004). A retrospective study (Ang et al. 2002) evaluated the 
EGFR expression in 155 patients with stage III-IV SCCHN accrued in the control 
arm of RTOG 9003 study, andreceived exclusive external beam RT (70 Gy in 7 
weeks). A detectable expression of EGFR was found in 148/155 patients (95%), 
with a wide range in interindividual variability. In this study, EGFR expression 
was found to be independent from tumor stage or initial nodal involvement; in 
multivariated analysis, it showed to be an independent pronostic factor of overall 
survival (P = 0.006) and of disease-free survival (P = 0.003), as well as a robust 
pronostic factor of locoregional relapse (P = 0.002) but not of distant relapse (P = 
0.50).  
If quantitative evaluation of EGFR by immunohistochemistry has 
emerged so far as a convenient and promising marker for clinical outcome 
correlation, a more accurate reflection of the "activity state" of EGFR signalling 
status might be provided by the phosphorylated or "activated" forms of EGFR 
downstream signalling molecules like phosphorylated MAPK, phosphorylated 
AKT or Stat-3 (Albanell et al. 2001) (Hambek et al. 2005). They are currently 
actively evaluated as potential surrogate markers of EGFR signalling in clinical 
therapeutic trials. 
 
 
 
1.5 Gefitinib 
 
Gefitinib (ZD1839, Iressa; AstraZeneca) is a potent and seletive inhibitor of 
EGFR tyrosine kinase in vitro, inhibits the growt of a wide range of human 
tumors xenografts in nede mice in a dose-dependent and reversible manner. 
(Barker et al. 2001) (Stamos et al. 2002). It is a quinazoline analogue (showed in 
Figure 3) and was approved by the FDA on May 2003 as a third line therapy for 
non-small cell lung cancer that is unresponsive to cisplatin and docetaxel (Cohen 
et al. 2003). Gefitinib was the first orally available EGFR tyrosine kinase inhibitor 
(TKI), to undergo clinical evaluation in human cancer and works as a potent and 
specific EGFR tyrosine kinase inhibitor (EGFR-TKI) by competing with 
adenosine triphosphate for the binding site on the intracellular domain of the 
receptor and by noncompetitively inhibiting epidermal growth factor peptide 
ligand 
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               Figure 3: Molecular structure of gefitinib 
 
 
.  
A preclinical rationale for gefitinib use in HNC has been provided by Di 
Gennaro et al (2003). In their studies gefitinib induced growth arrest in HNC cell 
lines by inhibiting EGFR-mediated signalling; cell cycle kinetic analysis 
demonstrated that gefitinib induced a delay in cell cycle progression and a G1 
arrest together with a partial G2/M block; this was associated with increased 
expression of both p27KIP1 and p21CIP1/WAF1.  
Gefitinib radiosensitize tumor cells by a variety of mechanisms, including 
reduction in the proportion of cells in the radioresistant S phase by inducing 
G0/G1 cell cycle arrest, inhibition of RT-induced damage repair, and induction of 
apoptosis (Herbst and O’Reilly 2003). Gefitinib has been shown to inhibit repair 
of RT-induced DNA double-strand breaks and enhanced radiosensitivity in HNC 
cells. (Shintani et al 2003).  
EGFR expression levels in head and neck cancer cell lines correlated with 
increased RT resistance (Akimoto et al. 1999).(Shintani et al. 2003). In xenograft 
tumor models, gefitinib in combination with RT resulted in synergistic growth 
inhibition. (Ochs, 2004). Al-Hazzaa et al(2005) observed a significant decrease in 
the percentage of surviving cells on treatment with gefitinib and cisplatin 
(CDDP) compared with CDDP or gefitinib alone in a human HNC cell line. 
Gefitinib applied before RT and before and/or during CDDP/fluorouracil 
improved the cytotoxic effect in HNC cell lines. As several preclinical studies 
have shown the synergistic activity between gefitinib and several cytotoxic drugs, 
such as cisplatin and 5-fluorouracyl, further clinical studies were performed 
(Magne et al. 2002 ).  
Thus, combining gefitinib with RT or chemoradiotherapy showed 
cooperative effects in preclinical studies and warranted clinical investigation in 
 16 
patients with locally advanced HNC patiemts (Ciardiello et al. 2000) (Sirotnak et 
al. 2000) 
Phase I studies indicated that gefitinib monotherapy was well tolerated, 
generally with mild, manageable, and reversible adverse effects at doses up to 
600 mg/d. The dose used is 250-500 mg / day in a single administration that is far 
below the maximum tolerated dose of 700 mg. The most frequent drug-related 
adverse events were acne-like skin rash in 46% to 64% of patients and diarrhea in 
47% to 55% of patients, reversible after discontinuation of treatment.(Baselga et 
al. 2002) (Herbst et al. 2002). Daily administration of gefitinib is safe, with dose-
dependent pharmacokinetics but with a high degree of interpatient variability 
(Ranson et al. 2002), (Nakagawa et al. 2003). Gefitinib significantly suppressed 
EGFR phosphorylation, inhibited MAPK activation, reduced keratinocyte 
proliferation and increased p27 levels and apoptosis (Baselga et al. 2002).  
 
The first clinical trial of gefitinib (500 mg/day) in recurrent or metastatic 
squamous cell HNC was run by Cohen (2003); a 10.6% response rate and a 53% 
disease control rate were reported; median progression free survival (PFS) was 
3.4 months in this study, while median overall survival (OS) was 8.1 months A 
daily dose of 500 mg was well tolerated, with grade 1 to 2 skin rash in 48% of 
patients, grade 1 to 2 diarrhea in 42% of patients, and grade 3 diarrhea in 6% of 
the patients. In another phase II clinical and molecular trial, gefitinib at the dose 
of 500 mg was tested in 32 patients with recurrent squamous cell HNC. In cohort 
A (no previous chemotherapy) 3 partial response (PR) and 6 stable disease (SD) 
were observed out of 20 patients (clinical benefit = 45 %). In cohort B (one 
previous chemotherapy) 3 out of 12 patients achieved SD (clinical benefit 25%). 
Median duration of response was 6 months in the overall patient population; 
median time to progression was 3 months and median survival was 6 months. 
(Wheeler et al. 2005) The results of an expanded access program of gefitinib as 
palliative treatment in recurrent or metastatic HNC have been recently reported. 
Response rate was much lower than in the Cohen study (8%), while disease 
control was achieved in 36% of patients; median time to progression was 2.6 
months, while median survival was 4.3 months (Kirbi et al. 2006). 
The comparison of the 2 above studies indicated a substantially better 
outcome in the first, which can be partially explained by the different patient 
characteristics in the 2 studies. 
Further efforts in the use of gefitinib in patients with recurrent/metastatic 
HNC included the use of a lower gefitinib dose (250 mg daily) (Cohen et al. 
2005,), in keeping with prior studies in non-small cell lung cancer patients which 
showed similar efficacy for the 250 and 500 mg daily doses but better tolerability 
for the lower dose (Fukuoka et al. 2003) (Kris 2003). Unfortunately, this study 
showed that 250 mg gefitinib had less activity than 500 mg, with only one partial 
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response (giving an objective response of 1.4%), 33% stable disease rate, median 
progression free survival of 1.8 months and overall survival of 5.5 months.  
Chen and collegue (2007) conduced a phase I dose-escalation study of 
gefitinib in combination with RT or chemoradiotherapy in patients with local 
advanced HNC to establish the safety and toxicity profile regarding this 
therapeutic strategy. Because EGFR overexpression seems to be important in 
HNC carcinogenesis and HNC patients have increased risk in developing a 
secondary primary tumor and distant metastasis, was studied also the safety, 
feasibility, and toxicity profile of protracted administration of gefitinib as 
maintenance therapy for a period of up to 2 years. Two patients had stable 
disease, and the rest (91%) had a clinical complete response in the primary tumor. 
With a median follow-up time of 26.3 months (range, 5 to 54.4 months, the 
estimated rates of 1-year Locoregional Control. Disease Free-Survival and 
Overall survival  were 91%, 82%, and 87%, respectively; and  at 3 years, these 
rates were 85%, 61%, and 74%, respectively. This study howed that gefitinib 
500mg daily and definitive RT were well tolerated. The profile of acute toxicity 
during concurrent gefitinib and chemoradiotherapy was consistent with the 
toxicity profile reported in the larger chemoradiotherapy trials. Gefitinib does not 
seem to increase chemoradiotherapy-related mucositis and skin reaction. 
Gefitinib monotherapy has undergone a phase III evaluation within a 
randomized trial of two different doses of gefitinib (250 and 500 mg/daily) and 
weekly methotrexate, given at the dose of 40 mg/m2. Final data of this study, 
which was run in patients with recurrent or metastatic squamous cell HNC, with 
the collaboration of our cancer center, have been recently preliminary presented , 
and no differences in overall survival, response rates, toxicities were observed 
among the 3 treatment arms (Simon et al. 2007). As for all biologic drugs, single 
agent studies have paved the way to combinations with other therapeutic 
modalities, among which radiation therapy. Following initial reports of enhanced 
radiation response with anti-EGFR therapies, the confirmation of improved local 
tumor control in animal model systems using median tissue culture dose 
experiments was reported examples of specific mechanisms for enhancement of 
radiation response include the capacity of EGFR inhibitors to abrogate radiation-
induced phosphorylation of EGFR, to enhance radiation-induced apoptosis and 
attenuate radiation-induced expression of DNA repair proteins (Harari and Huang 
2006).  
To the best of our knowledge, this is the first study of gefitinib and 
radiotherapy, used togheter without concomitant chemoterapy, to be carried out 
in locally advanced inoperable squamous cell HNC. 
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2.   AIMS OF THE STUDY 
 
 
The aim of the present study was to clinically evaluate the combination of 
radiation therapy and an EGFR-tyrosine kinase inhibitor, such as gefitinib. 
In the present trial, two different doses of gefitinib (250 and 500 mg daily), 
administered along with standard radiation therapy, were tested in locally 
advanced inoperable squamous cell HNC. 
The primary objective of the dose finding part of the trial (phase I) is to 
identift the maximum totelated dose (MDT) of daily ZD1829 when used in 
combination with a standard radiotherapy regimen.  
The primary objective of the main phase II part of this trial is to assess the 
activity of the selected dose of ZD1839 in combination with the standard 
radiotherapy regimen by estimating the ovarall response rate by estimating the 
complete response (CR) rate, the partial response rate (PR) , the duration of 
response, progression-free survival; overall survival.  
The characterization of the safety profile and tolerability of gefitinib alone 
and of the combination was a further endpoint of the study. 
 
 
 
 19 
3.   MATERIALS AND METHODS 
 
 
3.1 Patients selection  
 
Eligibility criteria for study entry included male and female patients aged 18 to 
75 years, with newly diagnosed, histologically-confirmed, inoperable, locally 
advanced squamous cell carcinoma of the head and neck (undifferentiated 
nasopharyngeal carcinoma was not allowed), who have neiver received 
radiotherapy or chemotherapy or undergone surgery for head and neck 
carcinoma, with at least one bidimensionally measurable target lesion according 
to Response Critera Evaluation in Solid Tumors (RECIST) ; WHO performance 
status (PS) 0 or 1; life expectancy of at least 3 months; adequate baseline organ 
function defined as absolute neutrophil count (ANC) ≥ 2000 x 109 /l, platelets ≥ 
100,000 x 109 /l, bilirubin ≤ 1.5 mg/dl, serum transaminases ≤ 2.5 times the upper 
limit of reference range (ULRR) in absence of liver metastases or < 5 times the 
ULRR in the presence of liver metastases, serum creatinine < 1.25 times the 
ULRR.  
 Patients with a history of other co-existing malignancies or malignancies 
diagnosed within the last 5 years, with the exception of adequately treated cone-
biopsed in situ carcinoma of the cervix uteri and basal or squamous cell 
carcinoma of the skin, were also ineligible. 
 Pregnancy, lactation, uncontrolled infections, unstable systemic diseases, 
any evidence of clinically active interstitial lung disease and any unresolved 
chronic toxicity Common Toxicity Criteria (CTC) grade 2 were also exclusion 
criteria. Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin 
or St John’s Wort was not allowed because this drugs induce CYP3A4 and may 
decrease levels of gefitinib.  
The study was approved by the Ethics Committee of each participating 
center. Written informed consent was obtained from each patient before 
registration and may be discontinued from the trial treatment for withdrawal of 
informed consent, objective prgression of disease, dropouts, adverse events, 
ptotocol non-compliance or death.  
 The trial was performed in accordanse with principles of Good Clinical 
Practice.  
The study was sponsored by AstraZeneca (study no. 1839IL/0070, 
ClinicalTrials.gov Identifier: NCT00233636).  
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3.2 Trial design and treatment plan 
 
This was a multicentre, open-label, non-comparative, two step phase I/II study, 
with a dose-finding period to determine the MTD of daily gefitinib administered 
in combination with a standard radiotherapy regimen, followed by a phase II 
study to evaluate the therapeutic activity of the combination of the selected dose 
of gefitinib with a standard radiotherapy regimen. 
Gefitinib was administered once a day on a continuous basis. 
The treatment was administered for a maximum of 12 months or until 
disease progression, unacceptable toxicity or withdrawal of consent. The 
minimum amount of follow-up was 12 months.  
Radiotherapy with curative intent (a seven-to-eight-week course of 
treatment) was started concomitantly with gefitinib and was administered in daily 
fractions of 2.0 Gy. Wide treatment fields were planned to encompass the 
primary tumour and involved neck nodes and a total dose of 52.0 Gy was given 
to all patients. This was to be followed by a boost to the primary tumour bed, 
which was to receive at least 64.0 Gy. 
Cohorts of three patients were treated with gefitinib at first dose level 
(250 mg). If one or two patients in the initial cohort had dose-limiting toxicity 
(DLT), three other patients were enrolled at the same level.  
Dose escalation proceeded if no patients had DLT, which was defined as 
grade 3 to 4 haematologic, neurologic, cardiac (including prolungation of PR 
interval), lung, renal or hepatic toxicity; grade 3 to 4 weight loss with 
performance status deterioration; deterioration of visual acuity thought to be 
associated with gefitinib treatment, grade 3-4 skin toxicity outside the field of 
irradiation) or acute morbidity grades 3 to 4 in the radiation field, or 
gastrointestinal toxicity (stomatitis/oesophagitis or vomiting/diarrhea for more 
than 4 days despite aggressive symptomatic therapy) and grade 4 dysphagia.  
The required fon a naso-gastric feed tube as a result of grade 3-4 
stomatitis was considered a DLT.  
Dose escalation was stopped if more than a third of patients of a given 
cohort had DLT.  
The dose of gefitinib could be interrupted for a maximum of 14 days in 
the presence of grade 3 or 4 toxicity.  
Once the adverse event (AE) decreased in severity to grade 1, the patient 
continued to take the assigned dose. If the AE resolved to grade 2, patients in the 
500 mg cohort had their dose reduced to 250 mg, while patients in the 250 mg 
cohort were taken off study. 
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3.3 Patient evaluation 
 
At enrollment, patients were evaluated by a complete history and physical 
examination, performance status recording, heart rate and blood pressure, 
complete blood cell (CBC) count, serum chemistries, urinalysis, 
electrocardiogram (ECG), chest X-ray, total body computed tomography (CT) 
scan. Other exams were performed only in the presence of clinical indication. 
Patients were monitored throughout treatment by clinical examination, toxicity 
assessment, CBC counts, biochemistry, concurrent illness or therapy, on day 1 of 
each week during radiotherapy. ECG and ophthalmic assessment was performed 
as clinically indicated. 
During the combination trearment (Gefitinib plus Radiotherapy) visits 
were performed on days 1 to 5 of each week for aproximately 7 week, and the 
patients were monitored by clinical examination, toxicity assessment, CBC 
counts, biochemistry, concurrent illness or therapy. 
During the treatment with single-agent gefitinib, the patients were 
monitored by clinical examination, toxicity assessment, CBC counts, 
biochemistry, concurrent illness or therapy, and tumour assessment 4 weeks after 
the end of radiotherapy and at every 8 week-intervals thereafter until trial closure. 
Response was assessed according to Response Evaluation Criteria in Solid 
Tumors (RECIST). (Therasse et al. 2000)  
Responding or stable patients received additional treatment for a 
maximum of 12 months or until progression or unacceptable toxicities. National 
Cancer Institute (NCI) CTC were used to grade toxicity. 
Patient with progressive didease, unacceptable toxicity or withdraw 
consent withdrawn.  
Any ongoin trial treatment-releted toxicity or serious adverse events at 
withdrawal was monitored until resolution.  
At the trial closure, all patients assessed for survival.  
 
The trial flow chart is detailed in Figure 4.  
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Screening period: day -21 to 0
Patient informed consent, past mediacal history, ophtalmic history, 
demography, tumor assessment
Screening period: day -7 to 0
Patient concurrent illness, physical examination, haematology, biochemistry, 
Urinanalysis,  ECG, sample for EGFR expression
Combination treatment 
Visit on days 1 to 5 of each week for 7 weeks, Adverse events/toxicity every visit, 
Concurrent illness/therapy, 
physical examination, haematology, biochemistry, 
day 1 of every week ,  
Monotherapy with Gefitinib
Concurrent illness/therapy,  physical examination, haematology, biochemistry, 
Adverse events/toxicity Tumor assessment
 
Figure 4. Trial flow chart  
 
 
 
3.4 Statistical methods 
 
The standard “3+3” design was used for the phase I study. Fleming’s 
method was used to calculate the number of patients required in the phase II part 
of the study (13). A sample size of 28 patients receiving the MTD was to give 
more than 80% probability of rejecting a baseline response rate of 70% with an 
exact 5% one-sided significance test when the true response was at clinically 
relevant rate of 90%. The hypothesis that the response rate was equal to or less 
than the baseline was rejected if 23 or more responses were observed out of the 
28 patients.  
Objective Response rates (ORR) were summarised by proportions of 
patients responding by trial closure, intent to-treat population, together with a 
95% confidence interval.  
Progression free survival (PFS) was summarised by proportion of patients 
alive and profression-free with disease controlled at trial closure and was 
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calculated from the time of study entry until the first evidence of disease 
progression.  
Overall survival (OS) was summarised by proportion of patients alive at 
trial closure and was calculated from the time of study entry to patient’s death or 
last follow-up.   
The distribution of time-to-event variables was estimated by the Kaplan–
Meier method.  
Duartion of response was summarised by median time from objective 
response to progression or death. Only patients who responded are included in this 
analysis. 
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4.   RESULTS 
 
 
4.1 Patients characteristic  
 
Between July 2003 and March 2006, sixteen patients were enrolled in the 
study. Patients were ascertained also from subjects who referred to Dipartimento 
di Oncologia ed Endocrinologia  at “Federico II” University in Naples, Italy. 
The planned sample size was not reached due to the low accrual also for 
restrictive inclusion criteria. 
Twelve patients were male, four patients female. Median age was 58.5 
years (range 48-73). Performance status was 1 in the majority of patients. 
Hypopharynx was the most frequent site of primary tumor.  
Extensive lymhnnodes involvement was present in the majority of 
patients, with distant lymhnnodes involvement in 3 patients  
The characteristics of the eligible patients are detailed in table 1.  
 
Table 1: Characteristics of eligible patients (total n.= 16) 
 
Median Age (years) – range 58.5   (48-73) 
Sex (M/F) 12/4 
Perfomance status  
0 5 
1 11 
Primary site  
Hypopharynx 7 
Oral cavity 4 
Oropharynx 3 
Neck not-otherwise specified 1 
Parapharyngeal 1 
Regional lymph nodes involvement 9 
Distant lymph nodes involvement 3 
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4.2 Dose escalation results  
 
Two dose levels were tested. No DLT occurred among the first 3 patients treated 
at 250 mg, so gefitinib dose was escalated to 500 mg.  
Two patients had DLT among the first 3 patients treated at 500 mg; an 
additional patient treated at 500 mg had DLT; therefore, the accrual at the higher 
dose was stopped and further patients were treated at 250 mg.  
In total, twelve and four patients were enrolled at dose level of 250 mg 
and 500 mg, respectively. DLT observed at the higher dose included grade 3 
stomatitis in 3 patients and grade 3 liver toxicities in 1 patient. 
The dose level of 250 mg was recommended for the phase II study.  
The occurrence of adverse events represented the main cause of gefitinib 
interruption at both dose levels.  
Patient decision, liver toxicity, lung toxicity and low-compliance were 
additional reasons for treatment interruption in one case each.  
The median duration of gefitinib treatment was 100 days (range 36-272), 
and it was 27.4 % (range 9.9- 74.5%) of the maximum planned duration. 
The median total given dose of radiotherapy was 69 Gy (range 50-104). 
Radiotherapy was given for a median of 8 (range 7-13) weeks, which was slightly 
more than expected, and mainly owing to the occurrence of toxicity.  
 
 
 
4.3 Toxicity  
 
Six patients died during the study (3 patients treated at 250 mg and 3 patients at 
500 mg). In particular, two of these patients had a cardiovascular arrest; two other 
patients died of gastrointestinal toxicity (diarrhoea and dysphagia, respectively). 
The fifth patient passed away following an overwhelming sepsis, whereas the last 
patient died of an intratumoral hemorrhage.  
None of these deaths was considered related to gefitinib by any single 
investigators, whereas dysphagia was considered likely to be related to radiation 
therapy. 
Five serious adverse events (SAE) occurred in the subgroup of patients 
treated at 250 mg; three SAE were observed in the group of patients treated at 
500 mg.  
The overall incidence of treatment-induced serious adverse events was 
9%. Sixty-eight adverse events, which are detailed in table 2, were considered 
linked to the combination of gefitinib and radiotherapy.  
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Table 2: Number of adverse events related to the combination of gefitinib 
and radiotherapy  
Toxicities Number 
of AEs 
CTC 
Grade 1 
CTC 
Grade 2 
CTC 
Grade 3 
CTC 
Grade 4 
Stomatitis /  
Mucositis 14 6 4 4 -- 
Dysphagia 5 2 3 -- -- 
Diarrhoea 6 6 -- -- -- 
Vomiting 3 2 1 -- -- 
Anorexia 1 1 -- -- -- 
Fatigue 4 2 2 -- -- 
Anemia 1 -- -- -- 1 
Neutropenia 1 -- 1 -- -- 
Fever 1 1 -- -- -- 
Cough 1 1 -- -- -- 
Skin toxicities 11 8 3 -- -- 
Edema 3 2 1 -- -- 
Worsening of 
general condition 1 -- -- 1 -- 
Liver toxicities 7 3 -- 4 -- 
Weight loss 4 -- 4 -- -- 
Dysgeusia 1 -- 1 -- -- 
Radiation 
dermatitis 2 2 -- -- -- 
Mouth dryness 1 1 -- -- -- 
Erythema 1 1 -- -- -- 
AEs: Adverse Events; CTC: Common Toxicity Criteria 
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Table 3 details grade 3 toxicities observed at the two dose levels.  
 
Table 3: Grade 3- toxicities observed at the two  gefitinib dose levels 
 Grade 3 toxicities  Gefitinib dose level 250 mg 
Gefitinib dose level 
500 mg 
o Atherosclerosis  1 0 
o Mucositis  1 0 
o Hepatic toxicities  3 1 
o Stomatitis 0 3 
o Worsening of general  
conditions  0 1 
 
 
Table 4 details grade 4 toxicities observed at the two dose levels.  
 
 
Table 4: Grade 4 toxicities observed at the two  gefitinib dose levels 
 Grade 4 toxicities  Gefitinib dose level 250 mg 
Gefitinib dose lelve 
500 mg 
• Anemia  1 0 
• Hemorrhage  0 1 
• Infection  0 1 
• Cardiac arrest   1 1 
• Hypercalcemia 1 0 
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4.4 Response   
 
All sixteen patients were evaluable for response. The median duration of follow-
up was 8.3 months (range 2-26 months). At the time of study closure, 11 patients 
had died and 5 were alive. 
Four patients had a complete response, which was confirmed in 3 cases; 
eight patients had a partial response which was not confirmed in six. Stable 
disease and disease progression were observed in 1 and 3 patients, respectively. 
Median duration of response was 5.4 months (range 1-21 months). The observed 
stable disease lasted 7.4 months.  
The median progression free survival was 6.7 months (95% CI:4.5-12.1 
months  
The Kaplan-Meier plots for PFS is shown in figure 5  
 
 
Figure 5: Kaplan-Meier plot of progression free survival  
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The overall survival was 8.5 months (95%CI: 4.6- not reached).  
 
The Kaplan-Meier plots for OS is shown in figure 6  
 
 
Figure 6: Kaplan-Meier plot of overall survival 
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5.   DISCUSSION 
 
 
For many years, radiotherapy has been an acceptable option for patients with 
locoregionally advanced head and neck cancer. More recently, chemoradiotherapy 
has been found to improve locoregional control or survival over that with 
radiotherapy alone in selected groups of patients. (Pignon et al. 2000) (Pignon et 
al. 2004) 
Such combination regimens, however, are associated with high rates of 
severe and protracted mucositis and an increased need for nutritional support and 
invasive procedures for that purpose. as soon as late toxic effects, particularly 
swallowing dysfunction are also common. However, another phase III trial that 
evaluated chemotherapy combined with high-dose, fractionated radiotherapy, as 
compared with radiotherapy alone, found absolute increases in the duration of 
locoregional control and survival at two years of only 6 percentage points and 9 
percentage points (P > 0.10 for both comparisons), respectively (Staar et al. 2001) 
A considerable proportion of patients with head and neck cancer have 
reduced performance status or coexisting conditions, and these patients may be 
particularly prone to such adverse events. (Harari et al. 2003) (Denis et al. 2004) 
(Mittal et al. 2003) (Maguire et al. 2004). The generally greater toxicity of 
regimens of altered-fractionation radiotherapy places limits on the incremental 
improvements in efficacy gained by the addition of chemotherapy. In contrast, 
target therapy may make possible further gains in the efficacy of 
chemoradiotherapy regimens for head and neck cancer. 
 
Although, to the best of our knowledge, no other trials of gefinitib and 
radiotherapy only have been carried out, gefitinib has been widely tested in 
combination with radiochemotherapy, chemotherapy and biological therapy. The 
rationale for this studies was sound and preclinical data strongly supported them 
(Harari and Haung 2006). 
Ahmed and collegues (2007) have undertaken a study of gefitinib with a 
concurrent chemoradiation regimen followed by gefitinib adjuvant therapy in 
locally advanced disease. A very encouraging 91% complete response rate was 
observed in the study; estimated overall survival was 83% at 2 years, 73% at 3 
years while toxicity was consistent with chemoradiotherapy trials.  
Chen and collegue (2007) have recently published the data of a phase I 
trial of concurrent, daily gefitinib and radiation or chemoradiation for patients 
with locally advanced squamous cell HNC. Eligible patients were treated with 
daily gefitinib (250 or 500 mg) combined with either altered fraction radiation 
therapy alone or chemoradiotherapy in patients with intermediate or locally 
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advanced stage disease, respectively. Once the safety profile of gefitinib and 
radiotherapy was established, additional patients were accrued combining 
gefitinib with weekly cisplatin and concurred radiation therapy. The combination 
of gefitinib and radiotherapy was well tolerated at both gefitinib dose levels, with 
no significant increase in radiotherapy-induced toxicities. Increased toxicity was 
observed in patients also receiving chemotherapy, ald DLT included one grade 4 
diarrhea and one grade 4 neutropenic fever. Fifteen patients started mantainance 
gefitinib, and eight (53%) experienced grade 1-2 acne-like skin rash and diarrhea, 
but no grade 3 or 4 toxicity occurred.  
Among clinical studies of gefitinib and chemotherapy, the combination of 
gefitinib with docetaxel and cisplatin has been tested, and a median progression 
free survival of 5.1 months has been reported (Arias de la Vega et al. 2007)). 
More recently combination studies of other TKI, such as erlotinib and 
lapatinib, with radiation therapy have been started, but only very preliminary data 
are currently available.  
 
Significantly different data have been observed with the combination of 
radiation therapy and cetuximab, a chimeric monoclonal antibody targeting EGFR. 
This combined approach has shown improved survival with respect to radiation 
therapy alone in a randomized phase III trial in patients with locally advanced 
disease, thus qualifying as a possible new standard in this subset of patients 
(Bonner et al. 2006). The improvements in outcome achieved with radiotherapy 
plus cetuximab, as compared with radiotherapy alone (absolute survival benefit, 10 
percentage points at three years), compare favorably with the greatest increases in 
efficacy that have been demonstrated for chemoradiotherapy as compared with 
radiotherapy alone. (Pignon et al. 2004). 
The success of combining cetuximab with RT led to the ongoing Radiation 
Therapy Oncology Group 0522 phase III trial comparing chemoradiotherapy with 
chemoradiotherapy and cetuximab.  
Other monoclonal antibodies, such as panitumumab, a fully human 
monoclonal antibody anti-EGFR, have shown activity and are now under 
evaluation.  
 
Like NSCLC, the SCCHN harbors the EGFR mutations which might be 
responsible for the clinical response of gefitinib in the SCCHN patients. To 
explore this possibility, a recent Asian study has analyzed EGFR in 41 HNC 
patients for the detection of somatic mutations by PCR-single-strand 
conformational polymorphism analysis. Three EGFR mutations (7.3%) were 
detected in exon 19. However, non significant association with histologic or 
demographic variables was observed, thus suggesting a different etiology of 
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EGFR mutations in HNC with respect to non-small cell lung cancer (Lee et al. 
2005) 
The issue of the occurrence of EGFR mutations and sensitivity to TKI in 
HNC has also been investigated by Cohen and collaborators (2005). This study 
has shown the rarity of EGFR kinase mutation in unselected cases of HNC in 
American patients. 
Resistance to EGFR-targeted drugs may be related to abnormal activation 
of receptor downstream effectors which may render tumors insensitive to EGFR 
blockade. An intriguing area for investigation is the strategy of blocking two 
aspects of the same pathway. The combination of cetuximab plus gefitinib or 
erlotinib enhanced growth inhibition compared with either agent alone in a mouse 
xenograft model, suggesting that combined treatment with distinct EGFR 
inhibitory agents can augment the potency of EGFR signaling inhibitionThis 
concept may pave the way to clinical trials of combinations of EGFR-targeted 
drugs and downstream acting agents (Caponigro et al. 2006).  
Cancer cells have an ability to harness diverse growth factors signalling 
pathways for cell survival. The existence of these escape mechanisms reinforces 
the need for combination of targeted therapies, among which combination of anti-
EGFR therapies, and combination of therapies targeting EGFR and downstream 
effectors.  
Matar (2004). have studied the effect of the combination of gefitinib and 
cetuximab in a panel of human cancer cell lines and in an EGFR-dependent 
human tumor xenograft model (A431). The combined treatment with the two 
agents resulted in a synergistic effect on cell proliferation, a greater inhibition of 
EGFR-dependent signalling and induction of apoptosis.  
 
Clinical trials of combinations of EGFR-targeted drugs have recently 
started and the combination of gefitinib and cetuximab has proved feasible in 
HNC patients at the common dose of both agents, with hints of meaningful 
clinical activity . 
 
A phase II, randomized, double-blind, placebo-controlled, seven-arm, multicenter 
study sponsored by AstraZeneca Pharmaceuticals has completed patient accrual 
and is currently under analysis. The primary objective of the study was to assess 
the additive effect of gefitinib 250 or 500mg (administered either concomitantly or 
as maintenance) with CDDP plus RT in terms of local disease control and disease-
free survival rate at 2 years.  
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6.   CONCLUSION 
 
 
At the time of this trial drafting, radiotherapy was still the standard therapy in 
locoregional-disease. The role of chemotherapy was gradually, icreasingly 
acknowledged as effective when given concomitantly with radiation therapy  
The aim of the present study was to clinically evaluate the combination of 
radiation therapy and gefitinib. The dose of 250 mg daily was selected for phase 
II. Grade 3 stomatitis was the main dose-limiting toxicity of the combination in 
keeping with a possible worsening of radiotherapy toxic effect induced by 
gefitinib or also by decreased performance status (PS was 1 in the majority of 
patients). Six patients died during the treatment and although none of these deaths 
was considered related to gefitinib, some concern is raised by this occurrence. 
Furthermore, response and survival data were disappointing.  
A major limitation of the data is the lack of additional host-based prognostic 
factors and HNC consist of a heterogeneous collection of anatomic sites and cell 
types. Moreover, the planned sample size was not reached due to the low accrual, 
and hypopharynx was the most frequent site of primary tumor (the hypopharynx 
cancers have among the lowest relative survival rates of head and neck cancers 
with a 5-year relative survival rate about 30%). Moreover, extensive lymhnnodes 
involvement was present in the majority of patients, with distant lymhnnodes 
involvement in 3 patients 
 
We conclude that our study does not support further trials with gefitinib and 
radiation therapy according to the present schedule, in this patients population. 
Appropriate integration of gefitinib within chemoradiotherapy regimens and 
combination with other molecular targeted approaches including other 
antireceptor therapies, receptor-downstream signaling transduction inhibitors, and 
targeted approaches interfering with other essential drivers of cancer, such as 
angiogenesis, may represent a rational way forward and strong efforts are worth 
pursuing in this setting.  
 
Finally, well designed trials comparing this regimen with other forms of 
chemoradiotherapy are warranted. In the absence of these comparisons, 
physicians and patients should discuss the risks and benefits of each regimen on 
an individualized basis. 
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Background: Gefitinib, an orally active epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor, induces growth arrest in SCCHN cell lines 
mainly by blocking cells in G1 and preventing them from entering the cell cycle. 
Clinical studies have demonstrated the activity of gefitinib monotherapy in 
SCCHN. Preclinical studies have shown that the combination of RT and drugs 
interfering with the EGF pathway may result in radiosensitization in squamous 
cell carcinomas that over express EGFR. 
Methods: Pts with histologically confirmed, newly diagnosed, locally advanced 
inoperable SCCHN, never pretreated with surgery, chemotherapy or RT were 
enrolled into a phase I-II trial of gefitinib and RT. Two doses of gefitinib were 
tested (250 and 500 mg/day) in the dose-escalation phase and continued for 
up to 12 months; RT was administered concomitantly according to standard 
procedures (minimum of 52.0 grays; boost to the primary tumor site up to at 
least 64.0 grays). The recommended dose of gefitinib for phase II was 
determined by the dose-limiting toxicities (DLTs) observed during its combined 
administration with RT and for 2 weeks thereafter (phase I). Activity was 
evaluated 4 weeks after the end of the combined treatment and every 8 weeks 
thereafter, according to RECIST criteria. 
Results: 12 pts (9 M, 3 F, median age 58) have been evaluated thus far. The 
most common primary tumor site was the hypopharynx (5 cases); TNM stage 
was IV A (10 pts) and IV B (2 pts); tumor grades were 1 (2 pts), 2 (6 pts) and 3 
(4 pts). All pts completed the combined treatment according to the protocol. 
Total radiation dose was 60–74 grays. Overall best response was complete 
response in 3 pts, partial response in 5 pts, and unconfirmed partial response 
in 1 pt; 3 pts were not evaluable. Gefitinib-related grade 3 toxicities were 
mucositis (n = 1), liver toxicity (n = 1). RT-related grade 3 toxicities were 
stomatitis/mucositis (n = 5), general health deterioration (n = 1). Three pts died 
  
during treatment with gefitinib alone (not considered treatment related). DLT 
occurred in 3 pts treated with gefitinib 500 mg (grade 3 stomatitis, 3 pts [RT-
related]; grade 3 ALT increased, 1 pt [gefitinib-related]), and therefore 250 mg 
was selected as the recommended gefitinib dose for phase II. 
Conclusion: Accrual is continuing in the phase II trial. More mature data will 
be presented. 
IRESSA is a trademark of the AstraZeneca group of companies  
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Two different doses of gefitinib, administered along with
standard radiation therapy, were tested in locally advanced
inoperable head and neck cancer with the aim of finding
the maximum tolerated dose and assessing the toxicity
and activity of the combination. The standard ‘3+3’ design
was used for the phase I study. Radiation therapy was
given according to conventional dose and schedule.
Gefitinib dose escalation was stopped if more than
one-third of patients of a given cohort had dose-limiting
toxicity. Dose-limiting toxicity was observed in three of
four patients treated at the dose of 500mg, and included
grade 3 stomatitis in three patients and grade 3 liver
toxicities in one patient. The dose level of 250mg was
recommended for the phase II study. Six confirmed
objective responses were observed among 16 patients.
Our results do not support further trials with gefitinib
and radiation therapy, according to our schedule, in
this patient population. Integration of gefitinib within
chemoradiotherapy regimens and combination with
other biological therapies may represent the next
challenge. Anti-Cancer Drugs 19:739–744 c 2008
Wolters Kluwer Health | Lippincott Williams & Wilkins.
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Introduction
Head and neck cancer (HNC) is among the most
common cancers worldwide and squamous cell carcinoma
represents the most common histology. In most cases,
HNC is diagnosed as unresectable locally advanced
disease whose 5-year survival is less than 10% [1].
Combined chemoradiotherapy has represented the main-
stay of treatment over the last decades, but, disappoint-
ingly, patient outcome has not substantially improved.
Epidermal growth factor receptor (EGFR) is a 170-kDa
transmembrane glycoprotein receptor, which exerts
multiple functions through an intrinsic tyrosine kinase
activity, which is activated upon ligand binding. EGFR is
overexpressed in approximately 90% of HNC and has
been associated with worse prognosis, thereby providing
a rationale for clinical investigation of EGFR-targeting
drugs in HNC [2].
EGFR targeting can be considered as one of the most
exploited approaches to a rational targeted therapy of
cancer, and it can be basically achieved by either
monoclonal antibodies directed against the extracellular
domain of the receptor or by small molecules that act by
inhibiting EGFR-specific tyrosine kinases [3]. Gefitinib
was the first orally available EGFR–tyrosine kinase
inhibitor (TKI) to undergo clinical evaluation in human
cancer. A preclinical rationale for gefitinib use in HNC
has been provided by Di Gennaro et al. [4]. In their
studies, gefitinib induced growth arrest in HNC cell lines
by inhibiting EGFR-mediated signaling; cell cycle kinetic
analysis demonstrated that gefitinib induced a delay
in cell cycle progression and a G1 arrest together with
a partial G2/M block; this was associated with increased
expression of both p27KIP1 and p21CIP1/WAF1. The first
clinical trial of gefitinib (500mg/day) in recurrent or
metastatic squamous cell HNC was performed by Cohen
et al. [5]; a 10.6% response rate and a 53% disease control
rate were reported; median progression-free survival
(PFS) was 3.4 months in this study, whereas median
overall survival (OS) was 8.1 months. In another phase II
clinical and molecular trial, gefitinib at the dose of 500mg
was tested in 32 patients with recurrent squamous cell
HNC. In cohort A (no previous chemotherapy), three
partial responses (PRs) and six stable diseases (SDs)
were observed of 20 patients (clinical benefit= 45%). In
0959-4973 c 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins
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cohort B (one previous chemotherapy), three of 12
patients achieved SD (clinical benefit= 25%). Median
duration of response was 6 months in the overall patient
population; median time to progression was 3 months,
and median survival was 6 months. Importantly, no
association between changes in c-myc or cyclin D1 gene
expression and clinical benefit was observed [6]. The
results of an expanded access program of gefitinib as
palliative treatment in recurrent or metastatic HNC have
been recently reported. Response rate was much lower
than that in the Cohen study (8%), whereas disease
control was achieved in 36% of patients. Median time to
progression was 2.6 months, whereas median survival was
4.3 months [7]. The comparison of the two above studies
indicated a substantially better outcome in the first,
which can be partially explained by the different patient
characteristics in the two studies. Further efforts in the
use of gefitinib in patients with recurrent/metastatic
HNC included the use of a lower gefitinib dose (250mg
daily) [8]; in keeping with earlier studies in nonsmall cell
lung cancer (NSCLC) that showed similar efficacy for the
250 and 500mg daily doses, but better tolerability for the
lower dose [9,10]. Unfortunately, this study showed that
250mg gefitinib had less activity than 500mg, with only
one PR (giving an objective response of 1.4%), 33% SD
rate, median PFS of 1.8 months, and OS of 5.5 months
[8]. Gefitinib monotherapy has undergone a phase III
evaluation within a randomized trial of two different
doses of gefitinib (250 and 500mg/daily) and weekly
methotrexate, given at the dose of 40mg/m2. Final data of
this study, which was run in patients with recurrent or
metastatic squamous cell HNC, have been recently
presented, and no differences in OS, response rates,
and toxicities were observed among the three treatment
arms [11]. As for all biologic drugs, single agent studies
have paved the way to combinations with other
therapeutic modalities, among which is radiation therapy.
After initial reports of enhanced radiation response
with anti-EGFR therapies, the confirmation of improved
local tumor control in animal model systems using
median tissue culture dose experiments was reported
[12]. Examples of specific mechanisms for enhancement
of radiation response include the capacity of EGFR
inhibitors to abrogate radiation-induced phosphorylation
of EGFR, to enhance radiation-induced apoptosis, and
to attenuate radiation-induced expression of DNA repair
proteins [12].
Cetuximab, a chimeric monoclonal antibody targeting
EGFR, has been the first EGFR-targeting agent to be
used in combination with radiotherapy in HNC and
positive results have been reported. [13].
In the present trial, two different doses of gefitinib
(250 and 500mg daily), administered along with standard
radiation therapy, were tested in locally advanced
inoperable squamous cell HNC with the main aim of
finding the maximum tolerated dose (MTD) and asses-
sing the activity of the combination by estimating the
complete response (CR) rate, the PR rate, the duration of
response, progression-free survival, and OS. The char-
acterization of the safety profile of gefitinib alone and of
the combination was a further endpoint of the study.
To the best of our knowledge, this is the first study of
gefitinib and radiotherapy, used together without con-
comitant chemotherapy, to be carried out in locally
advanced inoperable squamous cell HNC.
Patients and methods
Patient selection
Eligibility criteria for study entry included histologically
confirmed, inoperable, and locally advanced squamous
cell carcinoma of the head and neck (undifferentiated
nasopharyngeal carcinoma was not allowed) with at least
one bidimensionally measurable target lesion; age 18–75
years; WHO performance status (PS) 0 or 1; life expectancy
of at least 3 months; and adequate baseline organ
function defined as absolute neutrophil count Z 2000
109/l, platelets Z 100 000 109/l, bilirubin r 1.5mg/dl,
serum transaminases r 2.5 times the upper limit of refer-
ence range (ULRR) in the absence of liver metastases or
less than five times the ULRR in the presence of liver
metastases, serum creatinine less than 1.25 times the
ULRR. Previous surgery was not allowed. Patients were
ineligible if they had received earlier radiotherapy or
chemotherapy. Patients with a history of other coexisting
malignancies or malignancies diagnosed within the last
5 years, with the exception of adequately treated cone-
biopsed in-situ carcinoma of the cervix uteri and basal or
squamous cell carcinoma of the skin, were also ineligible.
Pregnancy, lactation, uncontrolled infections, unstable
systemic diseases, any evidence of clinically active
interstitial lung disease, and any unresolved grade 2 or
higher Common Toxicity Criteria version 2.0 were
also exclusion criteria. Concomitant use of phenytoin,
carbamazepine, barbiturates, rifampicin, or St John’s
Wort was not allowed. The study was sponsored by
AstraZeneca, Basiglio, Italy (study no. 1839IL/0070,
Clinical Trials. gov Identifier: NCT00233636). The study
was approved by the Ethics Committee of each parti-
cipating center. Written informed consent was obtained
from each patient before registration.
Treatment plan
This was a multicenter, open-label, noncomparative, two
step phase I/II study, with a dose-finding period to
determine the MTD of daily gefitinib administered
in combination with a standard radiotherapy regimen,
followed by a phase II study to evaluate the therapeutic
activity of the combination of the selected dose of
gefitinib with a standard radiotherapy regimen.
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Gefitinib was administered once a day on a continuous
basis. The treatment was administered for a maximum of
12 months or until disease progression, unacceptable
toxicity or withdrawal of consent. The minimum amount
of follow-up was 12 months. Radiotherapy was started
concomitantly with gefitinib and was administered in
daily fractions of 2.0Gy according to the standard of each
participating center.
Cohorts of three patients were treated with gefitinib at
the first dose level (250mg). If one or two patients in the
initial cohort had dose-limiting toxicity (DLT), three
other patients were enrolled at the same level. Dose
escalation proceeded if no patients had DLT, which was
defined as grade 3–4 hematologic, neurologic, cardiac,
lung, renal, or hepatic toxicity; grade 3–4 weight loss
with PS deterioration; and deterioration of visual acuity
thought to be associated with gefitinib treatment, grade
3–4 skin or gastrointestinal toxicity, and grade 4
dysphagia. Dose escalation was stopped if more than
one-third of patients of a given cohort had DLT. The
dose of gefitinib could be interrupted for a maximum of
14 days in the presence of grade 3 or 4 toxicity. Once
the adverse event (AE) decreased in severity to grade 1,
the patient continued to take the assigned dose. If the
AE resolved to grade 2, patients in the 500mg cohort had
their dose reduced to 250mg, whereas patients in the
250mg cohort were taken off study.
Patient evaluation
At enrollment, patients were evaluated by complete
history and physical examination, PS recording, heart rate
and blood pressure, complete blood cell (CBC) count,
serum chemistries, urinalysis, ECG, chest radiograph, and
total body computed tomography scan. Other exams were
performed only in the presence of clinical indication.
Patients were monitored throughout the treatment by
clinical examination, toxicity assessment, CBC counts,
biochemistry, concurrent illness, or therapy on day 1 of
each week during radiotherapy. ECG and ophthalmic
assessment were performed as clinically indicated.
During the treatment with single-agent gefitinib, the
patients were monitored by clinical examination, toxicity
assessment, CBC counts, biochemistry, concurrent illness
or therapy, and tumor assessment 4 weeks after the end of
radiotherapy and at every 8-week interval thereafter until
trial closure. Response was assessed according to Re-
sponse Evaluation Criteria in Solid Tumors. Responding
or stable patients received additional treatment for
maximum of 12 months or until progression or unaccep-
table toxicities. National Cancer Institute Common
Toxicity Criteria version 2.0 were used to grade toxicity.
Statistical methods
The standard ‘3+3’ design was used for the phase I
study. O’Brien and Fleming’s method [14] was used to
calculate the number of patients required in the phase II
part of the study. A sample size of 28 patients receiving
the MTD was to give more than 80% probability of
rejecting a baseline response rate of 70% with an exact 5%
one-sided significance test when the true response was at
clinically relevant rate of 90%. The hypothesis that the
response rate was equal to or less than the baseline was
rejected if 23 responses or more were observed of the
28 patients. Response rates were summarized by propor-
tions together with a 95% confidence interval (CI). PFS
was calculated from the time of study entry to the first
evidence of disease progression; OS was calculated from
the time of study entry to patient’s death or last follow-
up. The Kaplan–Meier analysis was used for evaluation
of PFS and OS.
Results
Patient characteristics
Between July 2003 and March 2006, 16 patients were
enrolled in this study. The planned sample size was not
reached owing to the low accrual, which was likely
because of the increased awareness that concomitant
chemoradiotherapy was the best therapeutic option in
this subset of patients. Twelve patients were males, four
patients were females. Median age was 58.5 (range:
43–73) years. All patients had stage IV disease. PS was
1 in the majority of patients. Hypopharynx was the most
frequent site of primary tumor. The characteristics of the
eligible patients are summarized in Table 1.
Dose escalation results
Two dose levels were tested. No DLT occurred among
the first three patients treated at 250mg, so gefitinib
dose was escalated to 500mg. Two patients had DLT
among the first three patients treated at 500mg; an
additional patient treated at 500mg had DLT; therefore,
the accrual at the higher dose was stopped and further
patients were treated at 250mg. In total, 12 and four
patients were enrolled at dose level of 250mg and
500mg, respectively. DLT observed at the higher dose
included grade 3 stomatitis in three patients and grade 3
liver toxicities in one patient.
The dose level of 250mg was recommended for the phase
II study. The occurrence of AEs represented the main
cause of gefitinib interruption at both dose levels. Patient
Table 1 Characteristics of eligible patients (total n=16)
Median age (years) (range) 58.5 (43–73)
Sex (male/female) 12/4
Performance status 0 5
Performance status 1 11
Primary site
Hypopharynx 7
Oral cavity 4
Oropharynx 3
Neck not otherwise specified 1
Parapharyngeal 1
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decision (in two cases) and liver toxicity, lung toxicity,
and low compliance (in one case each) were additional
reasons for treatment interruption. The median duration
of gefitinib treatment was 100 (range: 36–272) days, and
it was 27.4 (range: 9.9–74.5%) of the maximum planned
duration. The median total given dose of radiotherapy
was 69 (range: 50–104) Gy. Radiotherapy was given for
a median of 8 (range: 7–13) weeks, which was slightly
more than expected, and mainly owing to the occurrence
of toxicities.
Toxicity
Six patients died during the study as a result of AEs
(three patients treated at 250mg and three patients
at 500mg). In particular, two of these patients had a
cardiovascular arrest and two other patients died of
gastrointestinal toxicity (diarrhea and dysphagia, respec-
tively). The fifth patient passed away after an over-
whelming sepsis, whereas the last patient died of an
intratumoral hemorrhage. None of these deaths was
considered related to gefitinib by any single investigators,
whereas dysphagia was considered likely to be related to
radiation therapy.
Five serious AEs (SAEs) occurred in the subgroup of
patients treated at 250mg; three SAEs were observed in
the group of patients treated at 500mg. The overall
incidence of treatment-induced SAEs was 9%. Sixty-eight
AEs, which are detailed in Table 2, were considered
linked to the combination of gefitinib and radiotherapy.
Table 3 details grade 3 and 4 overall toxicities observed at
the two dose levels.
Response
All sixteen patients were evaluable for response. The
median duration of follow-up was 8.3 (range: 2–26)
months. At the time of study closure, 11 patients had
died and five were alive. Four patients had a complete
response, which was confirmed in three cases; eight
patients had a PR, which was not confirmed in six
patients. SD and disease progression were observed in
one and three patients, respectively. Median duration
of response was 5.4 (range: 1–21) months. The observed
SD lasted 7.4 months. The median PFS was 6.7 months
(95% CI: 4.5–12.1) and the median OS was 8.5 months
(95% CI: 4.6–not reached). The Kaplan–Meier plots for
PFS and OS are shown in Figs 1 and 2, respectively.
Discussion
The aim of this study was to clinically evaluate the
combination of radiation therapy and an EGFR–TKI,
such as gefitinib. The rationale for this study was sound
and preclinical data strongly supported it [12]. The dose
of 250mg daily was selected for phase II. Grade 3
stomatitis was the main DLT of the combination in
keeping with a possible worsening of radiotherapy toxic
Table 2 Number of adverse events related to the combination of
gefitinib and radiotherapy
Toxicity
Number
of AEs
CTC
grade 1
CTC
grade 2
CTC
grade 3
CTC
grade 4
Stomatitis–mucositis 14 6 4 4 0
Dysphagia 5 2 3 0 0
Diarrhoea 6 6 0 0 0
Vomiting 3 2 1 0 0
Anorexia 1 1 0 0 0
Fatigue 4 2 2 0 0
Anemia 1 0 0 0 1
Neutropenia 1 0 1 0 0
Fever 1 1 0 0 0
Cough 1 1 0 0 0
Skin toxicities 11 8 3 0 0
Edema 3 2 1 0 0
Worsening of general
condition
1 0 0 1 0
Liver toxicities 7 3 0 4 0
Weight loss 4 0 4 0 0
Dysgeusia 1 0 1 0 0
Radiation dermatitis 2 2 0 0 0
Mouth dryness 1 1 0 0 0
Erythema 1 1 0 0 0
AEs, adverse events; CTC, Common Toxicity Criteria.
Table 3 Grade 3–4 overall toxicities observed at the two gefitinib
dose levels
Gefitinib dose level
250 mg
Gefitinib dose level
500 mg
Grade 3 toxicities
Atherosclerosis 1 0
Mucositis 1 0
Hepatic toxicities 3 1
Stomatitis 0 3
Worsening of general
conditions
0 1
Grade 4 toxicities
Anemia 1 0
Hemorrhage 0 1
Infection 0 1
Cardiac arrest 1 1
Hypercalcemia 1 0
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effect induced by gefitinib. Six patients died as a result of
AEs and although none of these deaths was considered
related to gefitinib, some concern is raised by this occur-
rence. Furthermore, response and survival data were
disappointing. Although, to the best of our knowledge, no
other trials of gefinitib and radiotherapy only have been
carried out, gefitinib has been widely tested in combina-
tion with radiochemotherapy, chemotherapy, and biologi-
cal therapy. Ahmed et al. [15] have undertaken a study of
gefitinib with a concurrent chemoradiation regimen
followed by gefitinib adjuvant therapy in locally advanced
disease. A very encouraging 91% complete response rate
was observed in the study; estimated OS was 83% at 2
years, 73% at 3 years whereas toxicity was consistent with
chemoradiotherapy trials. Chen et al. [16] have recently
published the data of a phase I trial of concurrent, daily
gefitinib and radiation or chemoradiation for patients with
locally advanced squamous cell HNC. Eligible patients
were treated with daily gefitinib (250 or 500mg)
combined with either altered fraction radiation therapy
alone or chemoradiotherapy in patients with intermediate
or locally advanced stage disease, respectively. Once the
safety profile of gefitinib and radiotherapy was estab-
lished, additional patients were accrued combining
gefitinib with weekly cisplatin and concurrent radiation
therapy. The combination of gefitinib and radiotherapy
was well tolerated at both gefitinib dose levels, with no
significant increase in radiotherapy-induced toxicities.
Increased toxicity was observed in patients also receiving
chemotherapy, and DLT included one grade 4 diarrhea
and one grade 4 neutropenic fever. Fifteen patients
started maintenance gefitinib, and eight (53%) experi-
enced grade 1–2 acne-like skin rash and diarrhea, but no
grade 3 or 4 toxicity occurred. Among clinical studies of
gefitinib and chemotherapy, the combination of gefitinib
with docetaxel and cisplatin has been tested, and a
median PFS of 5.1 months has been reported [17].
More recently, combination studies of other TKI, such as
erlotinib and lapatinib, with radiation therapy have been
started, but only very preliminary data are currently
available. In particular, a phase I/II study of erlotinib
with cisplatin and radiotherapy showed that the combina-
tion was safe and feasible [18], whereas results from an
ongoing phase I study of lapatinib in combination with
cisplatin and radiotherapy in locally advanced HNC demon-
strated minor AEs and encouraging clinical activity [19].
Significantly different data have been observed with
the combination of radiation therapy and cetuximab, a
chimeric monoclonal antibody targeting EGFR. This
combined approach has shown improved survival with
respect to radiation therapy alone in a randomized phase
III trial in patients with locally advanced disease, thus
qualifying as a possible new standard in this subset of
patients [13]. Other monoclonal antibodies, such as
panitumumab, a fully human monoclonal antibody anti-
EGFR, have shown activity and are now under evaluation.
A recent Asian study has analyzed EGFR in 41 HNC
patients for the detection of somatic mutations by PCR-
single-strand conformational polymorphism analysis.
Three EGFR mutations (7.3%) were detected in exon
19. However, nonsignificant association with histologic
or demographic variables was observed, thus suggesting
a different etiology of EGFR mutations in HNC with
respect to NSCLC [20]. The issue of the occurrence of
EGFR mutations and sensitivity to TKI in HNC has also
been investigated by Cohen et al. [21]. This study has
shown the rarity of EGFR kinase mutation in unselected
cases of HNC in American patients.
Cancer cells have an ability to harness diverse growth
factors signaling pathways for cell survival. The existence
of these escape mechanisms reinforces the need for
combination of targeted therapies, among which are
combination of anti-EGFR therapies and combination
of therapies targeting EGFR and downstream effectors.
Matar et al. [22] have studied the effect of the combi-
nation of gefitinib and cetuximab in a panel of human
cancer cell lines and in an EGFR-dependent human
tumor xenograft model (A431). The combined treatment
with the two agents resulted in a synergistic effect on cell
proliferation, a greater inhibition of EGFR-dependent
signaling, and induction of apoptosis [22]. Clinical trials
of combinations of EGFR-targeted drugs have recently
started and the combination of gefitinib and cetuximab
has proved feasible in HNC patients at the common dose
of both agents, with hints of meaningful clinical activity
[23]. Resistance to EGFR-targeted drugs may be related
to abnormal activation of receptor downstream effectors,
which may render tumors insensitive to EGFR blockade.
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This concept may pave the way to clinical trials of combi-
nations of EGFR-targeted drugs and downstream acting
agents [24]. In particular, phase I studies of gefitinib
and sorafenib [25] and of gefitinib and RAD-001 [26],
respectively, have been run in NSCLC and are both
showing preliminary hints of clinical activity.
We conclude that our study does not support further trials
with gefitinib and radiation therapy according to the pre-
sent schedule. Appropriate integration of gefitinib within
chemoradiotherapy regimens and combination with other
biological therapies may represent a rational way forward
and strong efforts are worth pursuing in this setting.
Acknowledgements
The authors acknowledge the support from AstraZeneca
for this study. Dr Mari is employed by AstraZeneca;
none of the other authors have any financial and personal
relationship with other people or organization that
could inappropriately influence their work. The study
was supported by AstraZeneca.
References
1 Reuter CW, Morgan MA, Eckardt A. Targeting EGF-receptor-signalling in
squamous cell carcinomas of the head and neck. Br J Cancer 2007;
96:408–416.
2 Santini J, Formento JL, Francoual M, Milano G, Schneider M, Dassonville O,
et al. Characterization, quantification, and potential clinical value of the
epidermal growth factor receptor in head and neck squamous cell
carcinomas. Head Neck 1991; 13:132–139.
3 Baselga J, Arteaga CL. Critical update and emerging trends in epidermal
growth factor receptor targeting in cancer. J Clin Oncol 2005; 23:
2445–2459.
4 Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M,
Abbruzzese A, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in
the antiproliferative effect of ZD1839 (‘Iressa’), an epidermal growth factor
receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma
cells. J Cell Physiol 2003; 195:139–150.
5 Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al. Phase
II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the
head and neck. J Clin Oncol 2003; 21:1980–1987.
6 Wheeler RH, Jones D, Sharma P, Davis RK, Spilker H, Boucher K, et al.
Clinical and molecular phase II study of gefitinib in patients (pts) with
recurrent squamous cell cancer of the head and neck (H&N Ca). Proc Am
Soc Clin Oncol 2005; 23 (Abstr 5531).
7 Kirby AM, A’Hern RP, D’Ambrosio C, Tanay M, Syrigos KN, Rogers SJ, et al.
Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic
head and neck cancer. Br J Cancer 2006; 94:631–636.
8 Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, et al.
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or
metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res
2005; 11:8418–8424.
9 Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al.
Multi-institutional randomized phase II trial of gefitinib for previously treated
patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin
Oncol 2003; 21:2237–2246.
10 Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al.
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor
tyrosine kinase, in symptomatic patients with non-small cell lung cancer:
a randomized trial. JAMA 2003; 290:2149–2158.
11 Stewart J, Simon W, Cohen Ezra EW, Licitra L. A phase III randomized
parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX)
in patients with recurrent squamous cell carcinoma of the head and neck.
Proc Am Ass Cancer Res 2007; 20 (Abstr 3522).
12 Harari PM, Huang S. Radiation combined with EGFR signal inhibitors:
head and neck cancer focus. Semin Radiat Oncol 2006; 16:38–44.
13 Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al.
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med 2006; 354:567–578.
14 O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials.
Biometrics 1979; 35:549–556.
15 Ahmed SM, Cohen EE, Haraf DJ, Stenson KM, Blair E, Brockstein BE, et al.
Updated results of a phase II trial integrating gefitinib (G), into concurrent
chemoradiation (CRT) followed by G adjuvant therapy for locally advanced
head and neck cancer (HNC). Proc Am Soc Clin Oncol 2007; 25
(Abstr 6028).
16 Chen C, Kane M, Song J, Campana J, Raben A, Hu K, et al. Phase I trial
of gefitinib in combination with radiation or chemoradiation for patients with
locally advanced squamous cell head and neck cancer. J Clin Oncol 2007;
25:4880–4886.
17 Belo´n J, Irigoyen A, Rodrı´guez I, Escobar Y, Alonso J, Pastor P, et al.
Preliminary results of a phase II study to evaluate gefitinib combined with
docetaxel and cisplatin in patients with recurrent and/or metastatic
squamous-cell carcinoma of the head and neck. Proc Am Soc Clin Oncol
2005; 23 (Abstr 5563).
18 Arias de la Vega F, Heruzo I, de las Heras M, de la Torre A, del Rio L,
Contreras J, et al. Phase I/II study of concurrent erlotinib and chemoradiation
for post-resected locally advanced squamous head and neck cancer
(HNSCC): a GICOR study. Proc Am Soc Clin Oncol 2007; 25
(Abstr 16544).
19 Harrington KJ, Bourgis J, Nutting CM, Rosine D, Theodosiou AM,
Gardiner S, et al. A phase I, open-label study of lapatinib plus
chemoradiation in patients with locally advanced squamous cell
carcinoma of the head and neck (SCCHN). Proc Am Soc Clin
Oncol 2006; 24 (Abstr 5553).
20 Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, et al. Somatic
mutations of EGFR gene in squamous cell carcinoma of the head and neck.
Clin Cancer Res 2005; 11:2879–2882.
21 Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM,
et al. Response of some head and neck cancers to epidermal growth factor
receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2
rather than EGFR. Clin Cancer Res 2005; 11:8105–8108.
22 Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, et al.
Combined epidermal growth factor receptor targeting with the tyrosine
kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab
(IMC-C225): superiority over single-agent receptor targeting. Clin Cancer
Res 2004; 10:6487–6501.
23 Baselga J, Schoeffski P, Rojo F, Dumez H, Ramos FJ, Macarulla T, et al.
A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD)
study of the combination of two anti-EGFR therapies, the monoclonal
antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib
(G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC)
and non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2006;
24 (Abstr 3006).
24 Caponigro F, Milano A, Ottaiano A, Iaffaioli RV. Epidermal growth factor
receptor as a major anticancer drug target. Expert Opin Ther Targets 2006;
10:877–888.
25 Adjei SS, Mandrekar S, Marks RS, Hanson LJ, Aranguren D, Jett JR, et al.
A phase I study of BAY 43-9006 and gefitinib in patients with refractory or
recurrent non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol
2005; 23 (Abstr 3067).
26 Kris MG, Riely GJ, Azzoli CG, Heelan RT, Krug LM, Pao W, et al. Combined
inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in
patients with non-small cell lung cancer who have smoked cigarettes:
a phase II trial. Proc Am Soc Clin Oncol 2007; 25 (Abstr 7575).
744 Anti-Cancer Drugs 2008, Vol 19 No 7
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
